Ultrastructural localization of Charcot-Leyden crystal protein in human eosinophils and basophils

European Journal of Haematology

Volumn 58, Issue 1, 1997, Pages 56-66

  Calafat, J ^a   Janssen, H ^a   Knol, E F ^b   Weller, P F ^c   Egesten, A ^d  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b CENTRAL LABORATORY   (Netherlands)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

basophils; Charcot Leyden crystal protein; electron microscopy; eosinophils; immunogold; macrophages

Indexed keywords

CHARCOT LEYDEN CRYSTAL PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BASOPHIL; CONTROLLED STUDY; ELECTRON MICROSCOPY; EOSINOPHIL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STEM CELL;

EID: 0031031754     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1997.tb01411.x     Document Type: Article

References (23)

1. GLEICH GJ, ADOLPHSON CR, LEIFERMAN KM. The eosinophil. In: GALLIN JI, GOLDSTEIN IM, SNYDERMAN R, eds. Inflammation: basic principles and clinical correlates. Boca Raton: Raven Press, 1992: 663-700.
2. LICHTENSTEIN LM, BOCHNER BS. The role of basophils in asthma. Ann NY Acad Sci 1991: 626: 48-61.
3. WELLER PF, BACH DS, AUSTEN KF. Human eosinophil lysophospholipase: the sole component of Charcot-Leyden crystals. J Immunol 1982: 128: 1346-1349.
4. WELLER PF, BACH DS, AUSTEN KF. Biochemical characterization of human eosinophil Charcot-Leyden crystal protein (lysophospholipase). J Biol Chem 1984: 259: 15100-15105.
5. ACKERMAN SJ, ZHOU Z, TENEN DG, CLARK MA, Tu Y-P, IRVIN CG. Human eosinophil lysophospholipase (Charcot-Leyden crystal protein): molecular cloning, expression, and potential functions in asthma. In: GLEICH GJ, KAY AB, eds. Eosinophils 1992. New York: Marcel-Dekker, 1992: 21-54.
6. LEONIDAS DD, ELBERT BL, ZHOU Z, LEFFLER H, ACKERMAN SJ, ACHARYA KR. Crystal structure of human Charcot-Leyden crystal protein, an eosinophil lysophospholipase, identifies it as a new member of the carbohydrate-binding family of lectins. Curr Biol 1995: 3: 1379-1393.
7. DVORAK AM, LETOURNEAU L, LOGIN GR, WELLER PF, ACKERMAN SJ. Ultrastructural localization of the Charcot-Leyden crystal protein (lysophospholipase) to a distinct crystalloid-free granule population in mature human eosinophils. Blood 1988: 72: 150-158.
8. WELLER PF, GOETZL EJ, AUSTEN KF. Identification of human eosinophil lysophospholipase as the constituent of Charcot-Leyden crystals. Proc NatL Acad Sci USA 1980: 77: 7440-7443.
9. DVORAK AM, WELLER PF, MONAHAN-EARLEY RA, LETOURNEAU L, ACKERMAN SJ. Ultrastructural localization of Charcot-Leyden crystal protein (lysophospholipase) and peroxidase in macrophages, eosinophils, and extracellular matrix of the skin in the hypereosinophilic syndrome. Lab Invest 1990: 62: 590-607.
10. DVORAK AM, FURITSU T, LETOURNEAU L, ISHIZAKA T, ACKERMAN SJ. Mature eosinophils stimulated to develop in human cord blood mononuclear cell cultures supplemented with recombinent interleukin-5. Part 1. Piecemeal degranulation of specific granules and distribution of Charcot-Leyden Crystal protein. Am J Pathol 1991: 138: 69-82.
11. DVORAK AM, ACKERMAN SJ. Ultrastructural localization of the Charcot-Leyden crystal protein (lysophospholipase) to granules and intragranular crystals in mature human basophils. Lab Invest 1989: 60: 557-567.
12. DVORAK AM, ISHIZAKA T, LETOURNEAU L, ALBEE EA, MITSUI H, ACKERMAN SJ. Charcot-Leyden crystal protein distribution in basophils and its absence in mast cells that differentiate from human umbilical cord blood precursor cells cultured in murine fibroblast culture supernatant or in recombinant human c-kit ligand. J Histochem Cytochem 1994: 42: 251-263.
13. KOENDERMAN L, KOK PTM, HAMELIKNK ML, VERHOEVEN AJ, BRUIJNZEEL PLB. An improved method for the isolation of eosinophil and granulocytes from the peripheral blood of normal individuals. J Leuk Biol 1988: 44: 79-86.
14. BLOM M, TOOL ATJ, MUL FPJ, KNOL EF, Roos D, VERHOEVEN AJ. Eosinophils isolated with two different methods show different characteristics of activation. J Immunol Methods 1995: 178: 183-193.
15. DE BOER M, Roos D. Metabolic comparison between basophils and other leukocytes from human blood. J Immunol 1986: 136: 3447-3454.
16. KNOL EF, MUL FPJ, JANSSEN H, CALAFAT J, Roos D. Monitoring human basophil activation via CD63 monoclonal antibody 435. J Allergy Clin Immunol 1991: 88: 328-338.
17. BAINTON DF, FARQUHAR MG. Segregation and packaging of granule enzymes in eosinophil leukocytes. J Cell Biol 1970: 45: 54-73.
18. EGESTEN A, ALUMETS J, VON MECKLENBURG C, PALMEGREN M, OLSSON I. Localization of eosinophil cationic protein, major basic protein, and eosinophil peroxidase in human eosinophils by immunoelectron microscopic technique. J Histochem Cytochem 1986: 34: 1399-1403.
19. ZUCKER-FRANKLIN D. Electron microscopic study of human basophils. Blood 1967: 29: 878-890.
20. VON HEIJNE G, LILJESTRÖM P, MIKUS P, ANDERSSON H, NY T. The efficiency of the uncleaved secretion signal in the plasminogen activator inhibitor type 2 protein can be enhanced by point mutations that increase its hydrophobicity. J Biol Chem 1991: 23: 15240-15243.
21. WELLER PF. The immunobiology of eosinophils. N Engl J Med 1991: 324: 1110-1118.
22. HENSON PM, HENSON JE, FITTSCHEN C, BRATTON DL, RICHES DWH. Degranulation and secretion by phagocytic cells. In: GALLIN JI, GOLDSTEIN IM, SNYDERMAN R, eds. Inflammation: basic principles and clinical correlates. New York: Raven Press, 1992: 511-539.
23. STERN M, MEAGHER L, SAVILL J, HASLETT C. Apoptosis in human eosinophils. Programmed cell death in the eosinophil leads to phagocytosis by macrophages and is modulated by IL-5. J Immunol 1992: 148: 3543-3549.